This study looks at two treatments for women and men with advanced breast cancer that is hormone receptor positive and HER2 negative. It compares sacituzumab tirumotecan alone and with pembrolizumab to regular treatments chosen by their doctors. The main goal is to see if these treatments can help people live longer without their cancer getting worse.
The trial's ID number is NCT06312176. This is a Phase 3 trial, meaning it is looking at how well the treatments work and how safe they are. It is regulated by the FDA and aims to include about 1,200 participants.
Who can join
Adults aged 18 and older can join. This study is open to both men and women with specific types of advanced breast cancer. Participants need to have certain health conditions and cannot have had certain previous treatments. The trial team will confirm if someone is eligible.
Condition
Breast Neoplasms
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into one of three groups. One group receives sacituzumab tirumotecan alone. Another group gets both sacituzumab tirumotecan and pembrolizumab. The last group follows the treatment chosen by their doctor, which could be different types of chemotherapy. Everyone receives treatment until their cancer progresses or they choose to stop.
Where
This trial is enrolling at 46 locations. Recruiting sites are listed first.
AdventHealth Altamonte Springs ( Site 0021)
Altamonte Springs, Florida
Recruiting
Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032)
Thomasville, Georgia
Recruiting
Banner MD Anderson Cancer Center-Oncology ( Site 0004)
Gilbert, Arizona
Recruiting
Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015)
Midlothian, Virginia
Recruiting
Cancer and Blood Specialty Clinic ( Site 0001)
Los Alamitos, California
Recruiting
Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037)
Boston, Massachusetts
Recruiting
Greenebaum Comprehensive Cancer Center ( Site 0036)
Baltimore, Maryland
Recruiting
Hematology Oncology Associates of Rockland ( Site 0054)
Director of the Breast Cancer Center at NYU Langone’s Perlmutter Cancer Center. Treats breast cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Inaugural Jeffrey F. Moley Professor of Endocrine and Oncologic Surgery, WashU. Treats breast cancer. A surgeon is the doctor who removes cancer with an operation (adults). Recognized at state, national or international level.
Microsurgical breast reconstruction specialist, MSK. Treats breast cancer and mouth cancer. Offers microsurgical breast reconstruction, head and neck reconstruction and abdominal wall reconstruction.